4P Pharma Delta 4 sign agreement to identify and develop treatments for rare autoimmune chronic liver disease
4P-Pharma, a French clinical stage biotechnology company, and Delta 4, an Austrian digital drug development company, announced the signing of a collaboration agreement.
Under the agreement, both companies will jointly identify and develop first-in-class drug candidates for a rare autoimmune chronic liver disease for which currently no effective curative treatment is available.
Contributing to this collaboration, Delta 4 will apply its proprietary computational and iterative big data analytics platform to identify novel therapeutic targets and signalling pathways as well as drug candidates for a rare autoimmune chronic liver disease. Based on the results provided by Delta 4, 4P-Pharma will structure a tailored R&D maturation program with the focus to further characterize these candidates to demonstrate their potential for improving the treatment. Together, Delta 4
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!